STX 001
Alternative Names: STX-001Latest Information Update: 16 Sep 2025
At a glance
- Originator Massachusetts Institute of Technology
- Developer Strand Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins; RNA
- Mechanism of Action Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Malignant melanoma; Solid tumours; Triple negative breast cancer
Most Recent Events
- 30 May 2025 Efficacy, pharmacokinetics and adverse events data from a phase I/II trial in Solid tumours presented at the 61st Annual Meeting of the American Society of Clinical Oncology
- 26 May 2025 Efficacy and adverse events data from a phase I/II trial in Solid tumours released by Strand Therapeutics
- 03 May 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia (Injection) (NCT06249048)